AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care
LomustineGlioblastomaBrain NeoplasmsNeoplasm Recurrence, LocalDacarbazineProcarbazineAntineoplastic Agents, AlkylatingKarnofsky Performance StatusOligodendrogliomaAstrocytomaAntibodies, Monoclonal, HumanizedGliomaAngiogenesis InhibitorsDisease-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsVincristineTreatment OutcomeCarmustineSurvival RateCamptothecinCombined Modality TherapyAntineoplastic AgentsKaplan-Meier EstimateDrug Administration ScheduleMechlorethamineDisease ProgressionMagnetic Resonance ImagingSurvival AnalysisQuinazolinesVindesineSalvage TherapyMaximum Tolerated DosePrognosisChromosomes, Human, Pair 19Antibodies, MonoclonalRecurrenceBleomycinFollow-Up StudiesRetrospective StudiesTumor Markers, BiologicalChromosomes, Human, Pair 1Cell Line, TumorIdarubicinChemotherapy, AdjuvantHodgkin DiseaseSemustineAlkylating AgentsEncyclopedias as TopicEthyl MethanesulfonateNitrosourea Compounds
MultiformeTemozolomideBevacizumabHigh grade gliomaTumorsAstrocytomaPatients with glioblastomaProcarbazineGliomasChemotherapy drug lomustineSurvival for patients with recurrentEpidermal growth fOverall survivalBerubicin to LomustineTumorDiagnosisGleostineRadiotherapyGlioma patientsTreatment2023TherapyEflornithineTherapiesNSCLCMutations2021EfficacyPrimaryMolecular featuresAggressiveAstrocyticPhaseProgressionBrain cancerClinical Trial
Multiforme24
  • In this review, we will outline how systems biology has been instrumental in advancing precision oncology encompassing early detection, diagnosis monitoring and treatment, focusing on glioblastoma multiforme (GBM). (biomedcentral.com)
  • One of the most deadly and aggressive brain diseases now claiming many lives is glioblastoma, commonly known as glioblastoma multiforme (GBM). (marketdataforecast.com)
  • Additionally, several advancements have been made in procedures to remove tumors brought on by glioblastoma multiforme (GBM). (marketdataforecast.com)
  • The fast global spread of COVID-19 significantly influences the treatment of recurrent glioblastoma multiforme and other malignancies. (marketdataforecast.com)
  • In addition, the worldwide pharmaceutical supply chain has also been affected by this pandemic, which has made it more difficult for patients with recurrent glioblastoma multiforme to access and obtain therapy. (marketdataforecast.com)
  • The need for a personalized treatment strategy to handle glioblastoma multiforme is anticipated to rise due to tumor heterogeneity and variance in patient-to-patient treatment approaches. (marketdataforecast.com)
  • Furthermore, the approval of new therapies is expected to lengthen the life expectancy of glioblastoma multiforme patients. (marketdataforecast.com)
  • The primary constraints anticipated to restrain the growth of the glioblastoma multiforme are the lack of effective medicines and the inability of these therapies to prevent tumor recurrence effectively. (marketdataforecast.com)
  • The abstract titled " Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy," was presented in the Central Nervous System Tumors poster session by Dr. Hsu. (texaslatinonews.com)
  • The Company's ongoing global study is an adaptive, multicenter, open-label, randomized, controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV) after failure of standard first-line therapy evaluating efficacy and safety of Berubicin. (texaslatinonews.com)
  • This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM). (uci.edu)
  • Glioblastoma, previously known as glioblastoma multiforme, is the most aggressive among infiltrative gliomas, a group of primary tumors arising from the central nervous system (CNS). (cancernetwork.com)
  • The term 'glioblastoma multiforme' was introduced in the 1926 classification system devised by Cushing and Bailey. (cancernetwork.com)
  • 1] 'Multiforme,' which refers to a heterogenous histologic appearance and proliferation of multiple cell types, was abandoned from the revised nomenclature in the 2007 World Health Organization Classification of Tumors of the Central Nervous System, and is now simply called 'glioblastoma. (cancernetwork.com)
  • These include novel therapies for the treatment of primary brain tumors such as glioblastoma multiforme (GBM) and metastatic brain tumors that arise from cancers affecting the breast, lung or skin. (pacificneuroscienceinstitute.org)
  • Treatment of Glioblastoma Multiforme with Radiotherapy and Concomitant and Adjuvant Temozolomide: Translation of Randomised Controlled Trial Evidence into Routine Clinical Practice. (medscape.com)
  • This phase I study evaluated a Gene Mediated Cytotoxic Immunotherapy approach for malignant gliomas, including glioblastoma multiforme and anaplastic astrocytoma. (mountaintoday.in)
  • CNS Pharmaceuticals (NASDAQ: CNSP) , a clinical-stage biotechnology company specializing in the development of novel treatments, recently reported the enrolment of the first patient in Switzerland as a participant in its ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme ("GBM") ( https://nnw.fm/2oa0k ). (networknewswire.com)
  • Glioblastoma multiforme (GBM) is the most common brain tumour, characterized by a central and partially necrotic (i.e., hypoxic) core enriched in cancer stem cells (CSCs). (omicsdi.org)
  • Temozolomide (TMZ)-resistance in glioblastoma multiforme (GBM) has been linked to upregulation of O(6)-methylguanine-DNA methyltransferase (MGMT). (omicsdi.org)
  • Glioblastoma multiforme (GBM) is one of the most hypoxic tumors of the central nervous system. (omicsdi.org)
  • Glioblastoma multiforme (GBM) contains a population of cells that exhibit stem cell phenotypes. (omicsdi.org)
  • SAN DIEGO , April 12, 2021 /PRNewswire/ - Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or resistant to, current treatment regimens, today announced interim data results from two Phase 2 clinical trials evaluating VAL-083, the Company's lead compound, for the treatment of glioblastoma multiforme (GBM). (pennystocksreporter.com)
  • el glioblastoma multiforme (GBM) representa la forma más agresiva de los gliomas. (rmu.org.uy)
Temozolomide14
  • Concurrent treatment with adjuvant temozolomide and alternating electric fields is a National Comprehensive Cancer Network category 1 recommendation for treatment of newly diagnosed glioblastoma in patients 70 years of age or younger who have a good performance status (PS), and is considered a reasonable treatment option for patients older than 70 years of age with good PS. (medscape.com)
  • Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. (brainlife.org)
  • Tumour-treating fields (TTFields) have emerged as an additional treatment option in combination with maintenance temozolomide treatment for patients with newly diagnosed glioblastoma. (smw.ch)
  • The current chemotherapy options include nitrosoureas (e.g., lomustine) and the imidazotetrazine-class monofunctional DNA alkylating agent, temozolomide (TMZ). (oncotarget.com)
  • This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. (uci.edu)
  • Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (uci.edu)
  • Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma. (uci.edu)
  • This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. (uci.edu)
  • It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma. (uci.edu)
  • This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. (uci.edu)
  • Concomitant temozolomide chemotherapy was applied in 16 cases, combined temozolomide/lomustine chemotherapy was applied in one case and concomitant bevacizumab therapy in one case. (biomedcentral.com)
  • BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1? (omicsdi.org)
  • A phase I/II/IIb clinical trial with Fibromun in combination with radiotherapy and temozolomide in newly diagnosed glioblastoma ( NCT04443010 ). (philogen.com)
  • The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy. (mycancergenome.org)
Bevacizumab7
  • Bevacizumab prolongs progression-free survival in newly diagnosed and recurrent glioblastoma, but does not impact overall survival. (smw.ch)
  • Received any prior treatment with lomustine, agents part of any of the experimental arms, and bevacizumab or other vascular endothelial growth factor (VEGF) or VEGF receptor-mediated targeted agent. (dana-farber.org)
  • In contrast, efforts to improve the current standard of care of newly diagnosed glioblastoma (GB) with, for example, the addition of bevacizumab (BEV), have been largely disappointing and furthermore molecular characterization has not changed therapy except in elderly patients. (surgicalneurologyint.com)
  • Alymsys (bevacizumab-maly) is a biosimilar to Avastin (bevacizumab) that is used to treat a variety of cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. (mdtodate.com)
  • This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. (uci.edu)
  • Lomustine and Bevacizumab in Progressive Glioblastoma. (neoimmunetech.com)
  • ROG ) bevacizumab delays glioblastoma progression and death compared to chemotherapy alone, but it hasn't been proven to improve symptoms for survival. (investingnews.com)
High grade glioma2
  • Together, the presented data demonstrate Toca 511 & Toca FC continue to show potential benefits, including a favorable safety profile and extended overall survival (OS) in patients with recurrent high grade glioma (HGG) compared to historical benchmarks. (vporoom.com)
  • Fibromun has also shown promising activity in orthotopic mouse models of glioblastoma and in high-grade glioma patients (studies performed in collaboration with the University Hospital Zurich). (philogen.com)
Tumors8
  • Lomustine is an alkylating chemotherapy drug that is indicated by the FDA for the treatment of patients with brain tumors (primary and metastatic), following any necessary surgery and radiation, as well as for treatment of progressive Hodgkin's lymphoma. (wikipedia.org)
  • Lomustine is approved for the treatment of brain tumors, breast cancer, lung cancer, Hodgkin's lymphoma, and melanoma by Health Canada. (wikipedia.org)
  • Recent research indicates that secondary mutations detected in the RB and AKT-mTOR signaling pathways are linked to characteristics of recurrent tumors specific to TMZ-treated patients. (oncotarget.com)
  • Based on this data, a Phase 1 dose escalation study was conducted by a prior developer in patients with recurrent primary brain tumors. (texaslatinonews.com)
  • All of these are considered standard of care for recurrent tumors (which is important for insurance reasons), and can legally also be used for newly diagnosed patients as well. (gotomydoctor.com)
  • A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. (omicsdi.org)
  • Glioblastoma tumors are one of the most aggressive forms of cancer and yet have very few treatments. (investingnews.com)
  • To avoid enrollment of patients with glioblastoma , patients with Gd -contrast enhancing tumors will be eligible if there is no necrosis seen on MRI and any of the following criteria is true: 1. (mycancergenome.org)
Astrocytoma3
Patients with glioblastoma4
  • Research Article: Association of antidepressant drug use with outcome of patients with glioblastoma. (brainlife.org)
  • Using liquid biopsy technology as a new diagnostic method, innovative treatment strategies may be implemented for patients with glioblastoma to improve their outcomes. (spandidos-publications.com)
  • As previously announced, CNS Pharmaceuticals has reached the criteria required by the study protocol to conduct a pre-planned, non-binding futility analysis, which an independent Data Safety Monitoring Board (DSMB) will review to determine whether to recommend continuing the study as planned or modifying the study based on Berubicin showing potential value as a second-line treatment for patients with glioblastoma. (accesswire.com)
  • Up to 10% of patients with glioblastoma harbor a mutation in the IDH1 or IDH2 genes, an early event in gliomagenesis. (cancernetwork.com)
Procarbazine1
  • Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. (thieme-connect.de)
Gliomas4
  • Gliomas are intrinsic brain tumours, which are classified by the World Health Organization (WHO) into different grades of malignancy, with glioblastoma being the most frequent and most malignant subtype (WHO grade IV). (smw.ch)
  • Fifty to seventy per cent rated FET PET as being important for different aspects of the assessment of newly diagnosed gliomas, including differential diagnosis, delineation of tumour extent for biopsy guidance, and treatment planning such as surgery or radiotherapy, 95% for the diagnosis of recurrent glioma, and 68% for the diagnosis of recurrent brain metastases. (bvsalud.org)
  • In addition, a subgroup of lower-grade gliomas may carry molecular features and signatures similar to glioblastoma, with a similarly aggressive natural course,[4] for which an intensive treatment strategy is advocated. (cancernetwork.com)
  • Actual y, WHO grade III gliomas are not common as classification of central nervous system (CNS) tumours clas- glioblastomas. (bvsalud.org)
Chemotherapy drug lomustine1
  • A phase 2 study now underway combines the poliovirus therapy with the chemotherapy drug lomustine for patients with recurrent glioblastomas. (toppersonalhealth.com)
Survival for patients with recurrent1
  • A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial. (toppersonalhealth.com)
Epidermal growth f1
  • This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM). (ucbraid.org)
Overall survival6
  • BACKGROUND: The phase 2 REGOMA trial suggested an encouraging overall survival benefit in glioblastoma patients at first relapse treated with the multikinase inhibitor regorafenib. (bvsalud.org)
  • The primary endpoint of this study, being conducted in the United States and Europe , is overall survival (OS), with a projected 243 patients enrolled in a 2:1 randomization design (Berubicin:Lomustine). (texaslatinonews.com)
  • The DSMB will review the number of deaths in each arm to ensure that the overall survival of patients receiving Berubicin shows at least a statistically significant comparability to those receiving Lomustine. (accesswire.com)
  • The goal of NIT-120, which is an investigator-initiated trial (IIT) , is to evaluate the safety and effectiveness of NT-I7 and pembrolizumab, as well as the overall survival in patients with recurrent GBM. (neoimmunetech.com)
  • During this analysis, an independent data safety monitoring board (DSMB) closely examines the number of deaths in each treatment group to ensure that patients receiving Berubicin show a significant improvement in overall survival compared to those receiving Lomustine. (northcarolinadaily.com)
  • More specifically, it will assess the effect of Berubicin compared with Lomustine on Overall Survival ("OS"), its primary endpoint measure, one that is recognized by the Food and Drug Administration ("FDA") as the basis for approval of oncology drugs. (networknewswire.com)
Berubicin to Lomustine1
  • It is randomized and controlled, comparing Berubicin to Lomustine - a drug unapproved for this indication but still used as the standard of care - in adult patients with recurrent GBM (WHO Grade IV) after standard first-line therapy has failed. (northcarolinadaily.com)
Tumor10
  • Tumor-derived Biomarkers in Liquid Biopsy of Glioblastoma. (brainlife.org)
  • Research on application of tumor treating fields in glioblastoma: A bibliometric and visual analysis. (brainlife.org)
  • In June 2021, the FDA also granted Fast Track Designation for VBI-1901 for the treatment of recurrent GBM in patients with first tumor recurrence. (advfn.com)
  • The heterogeneity of glioblastoma can suppress immune cell function and lead to immune evasion, which presents a challenge in developing effective molecular therapies for tumor cells. (spandidos-publications.com)
  • Glioblastoma (GBM) is characterized by significant genetic heterogeneity among tumor cells. (spandidos-publications.com)
  • Availability of tumor tissue representative of GBM from initial definitive surgery and/or, recurrent surgery, if performed. (dana-farber.org)
  • Glioblastoma remains a lethal and devastating disease, despite advances in surgical and radiation therapies, as well as new chemotherapy and targeted agents," said Darell D. Bigner, M.D., Ph.D., emeritus director of The Preston Robert Tisch Brain Tumor Center at Duke and senior author of the study. (toppersonalhealth.com)
  • Glioblastoma is the most common malignant primary brain tumor, and this intractable cancer has a poor prognosis. (neoimmunetech.com)
  • Glioblastoma is an aggressive primary tumor of the central nervous system. (cancernetwork.com)
  • This is especially true for glioblastomas, which have a multiplicity of genetic aberrations that vary widely across individuals and sometimes even within the same tumor of a given individual. (gotomydoctor.com)
Diagnosis4
  • For instance, the Denovo biopharma drug DB102 (enzastaurin) was given fast-track designation by the US FDA in July 2020 for treating patients who had received a glioblastoma diagnosis. (marketdataforecast.com)
  • Since my own diagnosis of glioblastoma (GBM) in 1995 at age 50, I have spent considerable time researching treatment options, and the following discussion summarizes what I have learned. (gotomydoctor.com)
  • Since US Senator John McCain's glioblastoma diagnosis announcement in mid-2017 , the media has started asking a relatively unanswered question: what are glioblastoma treatment options ? (investingnews.com)
  • Exclusion Criteria: Patients who meet any of the following exclusion criteria are not eligible for study participation: - MRI defining progression is consistent with a diagnosis of glioblastoma or radiation necrosis. (mycancergenome.org)
Gleostine1
  • Lomustine is available in 5 mg (yellow capsule), 10 mg (white capsule), 40 mg (white & green capsule), and 100 mg (green capsule) gel capsules, referred to as Gleostine. (wikipedia.org)
Radiotherapy1
Glioma patients1
  • BACKGROUND: We evaluated O-(2-[ 18F]fluoroethyl)-L-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy. (bvsalud.org)
Treatment17
  • However, patients on Lomustine are advised not to breastfeed during the course of treatment due to the potential for serious adverse reactions to the drug. (wikipedia.org)
  • Lomustine is used as an "off-label" veterinary treatment for cancers in cats and dogs. (wikipedia.org)
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma (GBM). (advfn.com)
  • This paper explores the heterogeneity of glioblastoma and the immune microenvironment, providing a therapeutic basis for individualized treatment. (spandidos-publications.com)
  • We review here the development of system medicine approaches that model apoptosis for the treatment of cancer with a specific emphasis on the aggressive brain cancer, glioblastoma. (biomedcentral.com)
  • Consequently systemic therapy continues to be the most often utilized treatment in recurrent HGG. (surgicalneurologyint.com)
  • Alymsys, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). (mdtodate.com)
  • Alymsys is indicated for the treatment of recurrent glioblastoma (GBM) in adults. (mdtodate.com)
  • Alymsys, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer. (mdtodate.com)
  • Alymsys, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. (mdtodate.com)
  • It was shown that TMZ significantly increased the frequency of mutations in U87MG glioblastoma cells while DFMO-treated cells showed mutation frequency statistically similar to that of the untreated cells on the respective treatment days. (oncotarget.com)
  • This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma. (stanford.edu)
  • NeoImmuneTech, Inc. (NIT), a clinical-stage T cell-focused biopharmaceutical company, today announced the first patient dosed (FPD) in the phase II study NIT-120, which is investigating the combination of NT-I7 and pembrolizumab for the treatment of recurrent glioblastoma (GBM). (neoimmunetech.com)
  • This promising combination has potential for providing clinical advances in recurrent glioblastoma- a condition that currently has limited treatment options. (neoimmunetech.com)
  • As such, secondary glioblastomas are to be classified as a distinct biological and molecular entity for which different treatment strategies will ultimately be proposed. (cancernetwork.com)
  • With no approved treatment for recurrent GBM anywhere in the world, it is considered one of the greatest unmet needs in oncology. (northcarolinadaily.com)
  • Consistent with prior studies, myelosuppression is the most common adverse event with VAL-083 in both the recurrent GBM and adjuvant treatment settings. (pennystocksreporter.com)
20232
Therapy8
  • Neutrophil mediated drug delivery for targeted glioblastoma therapy: A comprehensive review. (brainlife.org)
  • 6. Lomustine-TMZ as maintenance therapy might improve survival in newly diagnosed patients compared to maintenance TMZ alone, as suggested by an open-label phase 3 trial in 141 patients, which demonstrated a HR of 0.6 (95% CI 0.35-1.03, p=0.0492) for the combined treatment9. (orlandohealth.com)
  • An 18-year collaboration with the National Cancer Institute's (NCI) Experimental Therapeutics (NExT) Program, NCI, part of the National Institutes of Health, and the U.S. Food and Drug Administration enabled the pre-clinical and translational phases of development of this novel therapy for glioblastoma. (toppersonalhealth.com)
  • This promising approach in glioblastoma therapy exemplifies the strategic investment made by the NCI to support the development of new therapies such as this one from research discovery into clinical trials. (toppersonalhealth.com)
  • This potentially pivotal, global study of Berubicin is an adaptive, multicenter, open-label, randomized controlled study in adult patients with recurrent GBM (WHO Grade IV) after failure of standard first-line therapy and compared to Lomustine as the standard of care (SOC). (accesswire.com)
  • Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. (medscape.com)
  • For this reason, CNS Pharmaceutical's adaptive, multicenter, open-label, randomized controlled study targets adult patients with recurrent GBM after failure of standard first-line therapy. (networknewswire.com)
  • Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. (omicsdi.org)
Eflornithine1
Therapies2
  • Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. (dana-farber.org)
  • In the upcoming years, the glioblastoma market is anticipated to be driven by the rising acceptance of innovative and combination therapies. (marketdataforecast.com)
NSCLC1
  • In June 2019, the U.S. Zirabev, a biosimilar to Avastin made by Pfizer, was given FDA approval to treat recurring cancers, including colorectal, NSCLC, and glioblastoma. (marketdataforecast.com)
Mutations1
  • Mutations in the isocitrate dehydrogenase (IDH) 1 or 2 genes are frequent in lower (WHO II/III) grade tumours but typically absent in classical glioblastoma. (smw.ch)
20211
Efficacy4
  • The Efficacy and Safety of Adjuvant Lomustine to Chemotherapy for Recurrent Glioblastoma: A Meta-analysis of Randomized Controlled Studies. (brainlife.org)
  • 5. TTFields - Large-scale, phase III clinical studies have validated the safety and efficacy of TTFields in patients with recurrent and newly diagnosed glioblastoma6,8. (orlandohealth.com)
  • Further evaluation of the orthotopic glioma models demonstrated that Berubicin had greater infiltration into intracranial glioblastoma cells compared to normal tissue, supporting the potential for improved efficacy. (texaslatinonews.com)
  • An interim analysis will evaluate the comparative effectiveness of these treatments, an adaptive design intended to demonstrate that Berubicin's efficacy is at least equal to that of Lomustine such that continuation of the study is in patients' best interests (futility analysis). (texaslatinonews.com)
Primary3
  • U87MG glioblastoma cell line characterized by chromosomal abnormalities commonly attributed to primary cancers was used as a model for this study. (oncotarget.com)
  • The majority of glioblastomas are IDH wild-type and correspond to the longstanding clinical description of primary glioblastomas, which arise rapidly from non-neoplastic brain cells and progress quickly. (cancernetwork.com)
  • In the past, both primary and secondary glioblastomas were considered to be the same clinical entity. (cancernetwork.com)
Molecular features1
  • This review focuses on clinical developments and management of newly diagnosed glioblastoma, and includes a discussion about the incorporation of molecular features into the classification of this disease. (cancernetwork.com)
Aggressive1
  • In October , the company announced that 229 out of 243 expected patients had already been enrolled in their ongoing study evaluating the effectiveness of Berubicin for recurrent GBM, a highly aggressive and incurable form of brain cancer. (northcarolinadaily.com)
Astrocytic1
  • 2] Glioblastoma is histologically defined by neoplastic cells with astrocytic characteristics and the presence of either endothelial proliferation-often in a glomeruloid morphology-and/or necrosis, which may resemble a pseudopalisading pattern (a false fence of neoplastic cells surrounding an area of necrotic tissue). (cancernetwork.com)
Phase4
  • The protein is currently in a phase 2b/3 clinical trial evaluating its effectiveness in treating platinum-resistant recurrent ovarian cancer, as well as non-small-cell lung cancers, urothelial, pancreatic cancer, uterine, HER negative breast cancers and clear renal cell carcinoma. (qualitystocks.com)
  • Poster CT238 provides an update from two patient groups receiving VAL-083 in an open-label, Phase 2 study in recurrent and adjuvant unmethylated GBM settings being conducted at the MD Anderson Cancer Center in Houston , Texas. (pennystocksreporter.com)
  • On the basis of the promising results observed in a phase I/II monotherapy study in patients with recurrent glioma, two clinical studies with registration potential have recently been started in newly diagnosed and in recurrent glioblastoma patients, respectively. (philogen.com)
  • A phase I/II clinical trial with Fibromun in combination with lomustine in grade III/IV glioma at first relapse ( NCT04573192 ). (philogen.com)
Progression1
Brain cancer1
Clinical Trial1
  • Investors should also consider clinical trial stocks, because treatments that break into the glioblastoma market that may delay early onset or even eliminate the disease should bring a high return. (investingnews.com)